Gastroenterology -Therapeutics & Hepatology

Hepatocellular Carcinoma: Latest Approaches

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, presents significant treatment challenges, especially in advanced stages. Recent advancements are transforming the management of HCC, offering new hope for improved outcomes. Targeted therapies, such as sorafenib and lenvatinib, have become standard for advanced HCC, providing substantial improvements in survival rates. Emerging treatments include novel multi-kinase inhibitors and immune checkpoint inhibitors, such as pembrolizumab and nivolumab, which have shown promise in enhancing the body's immune response against cancer cells. Additionally, locoregional therapies, such as transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), continue to evolve with more refined techniques and better outcomes. Recent research into combination therapies, integrating systemic treatments with locoregional approaches, is showing potential in improving efficacy. Advances in early detection through improved imaging technologies and biomarkers are also enhancing diagnosis and treatment planning. These latest approaches are advancing the management of HCC, leading to more effective and personalized treatment strategies.